Federal

;

House testimony on FY27 funding for domestic HIV and hepatitis programs

Apr 16, 2026 | ,

The HIV+Hepatitis Policy Institute respectfully submits this testimony in support of increased funding for domestic HIV and hepatitis programs at the Department of Health and Human Services for FY 2027. Specifically, this testimony is in support of funding for the following initiatives, programs and divisions: Ending the HIV Epidemic Initiative – $395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program – $3.13 billion; CDC Division of HIV Prevention – $822.7 million; CDC Division of Viral Hepatitis – $150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy – $7.6 million.  We also support maintaining funding for CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of Adolescent and School Health; the Minority HIV/AIDS Initiative; AIDS Research at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA Hepatitis C Elimination Initiative Pilot.

read more

Letter to the Dept. of Labor on improving transparency into pharmacy benefit manager fee disclosure

Apr 8, 2026 | ,

We strongly support the Department of Labor’s proposed rule to increase transparency in pharmacy benefit manager (PBM) compensation and financial arrangements. Greater transparency is essential to improving accountability across the prescription drug supply chain and ensuring that plan fiduciaries have the information necessary to assess the reasonableness of PBM contracts and practices. We urge the Department to finalize and implement this rule without delay, with the recommendations outlined in this letter.

read more

Comments to CCIIO on the 2027 Draft Letter to Issuers in the Federally-Facilitated Exchanges

Mar 23, 2026 | ,

We urge CMS to prioritize oversight of the Marketplace, which serves as an essential safety net within the country’s health insurance system and is of critical importance to people affected by HIV and other serious and chronic health conditions.  We urge CCIIO to reject proposals that decrease access to care by weakening network adequacy, time and distance, and ECP standards; enforce existing rules requiring copay assistance to count towards patient cost-sharing and that covered drugs are considered EHB; and improve the tools CMS provides to regulators to detect formulary coverage that deters enrollment by people living with HIV. As the key regulator of health insurance in the United States, we urge CCIIO to ensure that Marketplace plans provide meaningful, affordable, and non-discriminatory coverage to all. 

read more

Pin It on Pinterest